Home › NCT07191327
Testing Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy
Testing Personalized High Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy
Who can join
Ages 50 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis or symptoms consistent with PCA * Fluent in English * HD-tDCS compatible * Stable on relevant medications for at least approximately 4 weeks prior to study enrollment * If completing any additional, optional, long-term study visits in a remote location (i.e., not our office), a study partner is required in order to administer HD-tDCS. Those choosing to return to our office may have, but are not required to have, a study partner. Exclusion Criteria: * Other relevant neurological disease (e.g., epilepsy) or injuries (e.g., large vessel stroke, moderate-severe traumatic brain injury) viewed as primary to deficits since these could interfere with etiologic considerations and confound study results * Active, relevant psychiatric conditions (e.g., bipolar disorder, schizophrenia) since the symptoms of these conditions may confound study participation. * A recent (e.g., within the past 2 years) significant history of, or current, alcohol or drug abuse/dependence. Remote history of abuse/dependence is not exclusionary as long as it is not considered to be the primary etiology for visuospatial deficits. * Women that are lactating/breastfeeding, pregnant, or may potentially be pregnant will be excluded from the study.
About the study
This study is being completed to learn if high-definition transcranial direct current stimulation (HD-tDCS) has an effect on visual and thinking abilities in persons with posterior cortical atrophy (PCA). Participants will be randomized to receive real or sham HD-tDCS (8 sessions over 4 days).
Following the randomized treatment, participants will have optional open-label phase with real HD-tDCS up to 26 weeks and other possible testing.
What is being tested
- HD-tDCS sessions (device)
- Sham HD-tDCS sessions (device)
- HD-tDCS sessions - Open-label (after randomized treatment) (device)
Sponsor: University of Michigan · Participants: 50 · Started: Jan 28, 2026
Contact the study team
- Stephen Schlaefflin, BS · Phone: 734-936-7360
- Eileen Robinson, RN-BC · Phone: 734-763-1356
Official record on ClinicalTrials.gov — NCT07191327
Locations in the U.S.
| Michigan | University of Michigan, Ann Arbor |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.